Background Conversion surgery (CS) is expected as a new therapeutic strategy for patients with unresectable pancreatic cancer (UR-PC). We analyzed outcomes of CS for patients with UR-PC and evaluated the survival benefit of CS. Methods Thirty-four patients diagnosed with UR-PC according to the National Comprehensive Cancer Network guideline underwent CS in our hospital. Resectability was considered by multimodal images in patients who underwent nonsurgical treatment (NST) for more than 6 months. CS was performed only in patients who were judged to be able to undergo R0 resection. Results Twenty-six patients had locally advanced PC, and eight had distant metastases. The median duration of NST was 9 (range 5-44) months. R0 resection was achieved in 30 patients (88.2%). Six patients (17.6%) showed Evans grade ≥III. Three-and 5-year overall survival (OS) rates from initial treatment were 74% and 56.9%, respectively, with median survival time (MST) of 5.3 years. The actual 5-year OS rate in 19 patients was 47.4% with an MST of 4.0 years. Patients with Evans grade ≥III had a better prognosis than those with Evans grade <III (P = 0.0092, log-rank test). Conclusions Conversion surgery might have survival benefits to patients with UR-PC who responded favorably to NST.
Introduction
Pancreatic cancer (PC) is a representative disease of refractory malignant tumors, and its prognosis is the most dismal among gastrointestinal cancers. The number of patients with PC is increasing worldwide [1, 2] . In Japan, the number of deaths caused by PC reached 31,866 in 2015 [3] . Recently, although various diagnostic modalities have developed remarkably, detecting PC at its early stage is still difficult. Therefore, it is often diagnosed during its advanced stage, and resectable PC accounts for only 10-20% of all patients [4] . Furthermore, its prognosis is extremely poor, and the 5-year survival rate is less than 10% [5] . For pancreatic specialists, improving the prognosis of PC is the top priority, but trying to find solutions to surgical resection alone is obviously limited. It goes without saying that it is an urgent matter to establish an effective therapeutic strategy combined with multimodal treatment including surgical resection.
In recent years, patients with unresectable malignancies can obtain favorable treatment effect for a certain period of time by nonsurgical treatment (NST) such as chemo(radio) therapy and can be converted to surgical resection. This surgical strategy is called "conversion surgery (CS)" [6, 7] . Several articles have also been reported for CS in patients with unresectable PC (UR-PC) [8] [9] [10] [11] [12] [13] [14] [15] [16] , and its prognostic effect to CS has been mentioned. Hereafter, because of the remarkable progress of NST, candidates with UR-PC for CS are expected to increase. However, whether conversion ORIGINAL ARTICLE from NST with high treatment effect to CS brings true benefit to patients with UR-PC is unclear.
In this study, patients with UR-PC who underwent CS were retrospectively analyzed, and we aimed to clarify the survival benefit of CS for patients with UR-PC who obtain favorable treatment effect from NST.
Methods

Patients
Forty-three patients who were scheduled to undergo CS at the Department of Gastroenterological Surgery II, Hokkaido University Hospital, Japan, from April 2007 to October 2017 were identified as candidates of CS. Among them, nine patients were found to have unresectable lesion(s) after laparotomy. Then, the remaining 34 (79.1%) underwent CS. All patients had ductal adenocarcinoma of the pancreas cytologically or pathologically proved by endoscopic ultrasoundguided fine-needle aspiration. Multimodal image findings such as multidetector row computed tomography (MD-CT), contrast-enhanced ultrasonography (CE-US), gadoxetic acidenhanced magnetic resonance imaging (EOB-MRI), and positron emission tomography (PET) were considered, and we certainly confirmed that all patients had UR-PC initially according to the National Comprehensive Cancer Network (NCCN) guideline version 2.2017 [17] . In patients with a tumor that invaded the hepatic artery, the diagnosis of UR was made only when it involved the proper hepatic artery and extended up to the bifurcation of the right and left hepatic artery. The treatment effect of NST was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [18] . Our criteria in CS for patients with UR-PC were as follows: (1) treatment effect was evaluated as stable disease (SD), partial response (PR), or complete response (CR) in RECIST version 1.1 by NST for 6 months or more; (2) R0 resection was possible by multimodal imaging; (3) distant metastatic lesions should be resected when they showed no progression during NST and could be resected completely. If all metastases were treated with NST, resection of the primary lesion alone was performed. All patients met these criteria. Preoperative and postoperative clinical data were obtained from patients' medical records. Informed consent was obtained from all patients. This study was conducted with the approval of the Hokkaido University Hospital Institutional Review Board (017-0442, UMIN000031131).
Nonsurgical treatment
As to NST, there were no specific provisions for anticancer drugs and the combined use of radiation. Recently, FOLFIRINOX [5-fluorouracil (5-FU), oxaliplatin, irinotecan, and leucovorin] and combination therapy of nabpaclitaxel plus gemcitabine (GnP) were increasingly used due to the development of new therapies. With regard to the optimal treatment period of NST, we initially adapted "NST for more than 6 months" as the criteria, but according to Satoi et al. [9] , "NST for more than 8 months" was preferable if possible since 2014.
Conversion surgery
Conversion surgery for patients with PC was defined as follows: "The surgery for patients initially diagnosed with UR-PC who obtained favorable responses (SD, PR, or CR) as a result of NST for a certain period; the surgical resection was converted from NST which should be performed only when it was judged that R0 resection was possible considering multimodal image findings."
As imaging studies, US, MRI, three-phase MD-CT with multiplanar reconstruction image, endoscopic ultrasound, and PET were routinely used. When the following findings were found, patients were determined to undergo R0 resection: there did not appear to be any new distant metastases during NST; the tumor could be diagnosed as resectable or borderline PC because of shrinkage due to the effect of NST; or the tumor could be judged to be resected completely with concomitant major arterial resection even if it was diagnosed as UR-PC following NST.
Regarding the extent of resection, initially, all regions where the tumor existed at the time of initial diagnosis were included; as a result, extended resections, such as concomitant major arterial resection, were performed on patients with locally advanced PC. However, in recent years, high tumor reduction effects could be obtained according to the remarkable progress of NST; in some cases, it was very difficult to diagnose tumor extension correctly because of the influence of NST, even when using multimodal imaging. Given this situation, from 2014, we were positively trying to preserve major arteries by confirming the absence of cancer in the periarterial nerve plexus with intraoperative frozen sections and to minimize surgical invasiveness.
Assessment
The clinical treatment effect of NST was assessed by RECIST version 1.1 [18] , and the histologic assessment of the extent of NST response was evaluated by the Evans' grading system [19] . The Clavien-Dindo (C-D) classification was applied to postoperative complications [20] . On evaluation of CA19-9, "increase" indicated that patients who received NST had more than 20% increase in CA19-9 compared with the initial value, and "decrease" was defined as more than a 20% decrease in CA19-9. Others were defined as "no change." Mortality was defined as death within 90 days after surgery.
Statistical analysis
Continuous variables were reported as median and range. Overall survival (OS) was calculated from the date of initial treatment and CS to the date of last follow-up (censored) or the date of patient death (event). In the same way, disease-free survival (DFS) was also calculated from the date of CS to the date of the last follow-up (censored) or the date of confirmation of recurrence. Survival analysis was plotted according to the Kaplan-Meier method. Differences between the survival curves were analyzed by the generalized Wilcoxon (G-W) test and the log-rank (L-R) test. A P-value of <0.05 was considered significant. All analyses were performed using JMP Pro (version 13; SAS Institute Inc., Cary, NC, USA).
Results
Patients
Of the 43 patients, 34 (79.1%) patients could undergo CS, but the remaining nine patients underwent exploratory laparotomy. These nine patients had unresectable factors: specifically, five patients had hepatic metastases, two patients had peritoneal dissemination, and two patients were confirmed to have superior mesenteric artery (SMA) invasion of the tumor that exceeded 180°intraoperatively. Of the 34 patients who underwent CS, 16 patients were men and 18 patients were women, and the median age was 64 (range 43-80) years (Table 1) . Fifteen patients had tumor in the pancreatic head region, nine patients in the pancreatic body, four patients in the pancreatic tail, and six patients in the two regions (head/body or body/ tail). In unresectable tumors, 26 patients (76.5%) had locally advanced PC, and eight patients (23.5%) had distant metastasis. Among 26 patients with locally advanced PC, tumor contact with common hepatic artery (CHA) was most frequent in 12 patients; SMA in six patients; and celiac axis (CA), CA + CHA, or portal vein (PV) in two patients. Of the eight patients with distant metastasis, five patients had liver metastasis, two patients had paraaortic lymph node metastasis, and one patient had peritoneal dissemination.
Nonsurgical treatment
Eighteen patients received systemic chemotherapy, 13 patients received chemoradiotherapy, and three patients received intraarterial chemotherapy (Table 1) . In systemic chemotherapy, gemcitabine and S-1 combination therapy (GS), which is the most commonly used therapy in this study, was given to 10 patients. Three patients received gemcitabine (GEM) alone. GnP regimen or FOLFIRINOX were given to two patients. One patient with peritoneal dissemination was given intraperitoneal paclitaxel (PTX) combined with GEM administered intravenously. Intraarterial infusion chemotherapy with GEM and 5-FU was given in three patients. In terms of chemoradiotherapy, radiation therapy was combined with S-1 in eight patients, with GEM in three patients, with GS in one patient, and with GnP regimen in one patient. The total dose and fractions of radiotherapy were 50.4 Gy/25 fractions in 11 patients, 45 Gy/25 fractions in one patient, and 30 Gy/15 fractions in one patient. In addition, systemic chemotherapies were performed before or after chemoradiotherapy. The median NST period was 9 (range 5-44) months. The treatment effects of PR and SD were evaluated in 24 and 10 patients, respectively. No patients had CR according to preoperative images. Although CA19-9 levels were decreased by NST in 20 patients (58.8%), CA19-9 was elevated in only one patient (2.9%).
Surgical outcomes
We performed subtotal stomach-preserving pancreaticoduodenectomy in 12 patients, distal pancreatectomy with en bloc celiac axis resection in eight patients (Table 2) , concomitant CHA resection was in five patients, and concomitant portal vein resection was in 25 patients (76.5%). In four patients, we could avoid concomitant major arterial resection if the periarterial nerve plexus was cancer negative by intraoperative frozen sections. Including these four patients, R0 resection was achieved in 30 patients (88.2%). The median surgical time in all patients was 504.5 (range 200-1,159) min, and the median intraoperative bleeding was 997.5 (range 200-3,200) ml. Although complications of C-D classification ≥IIIa were found in eight patients (23.5%), no mortalities were reported in all patients. The median postoperative hospital stay was 28 (range 12-121) days. Histopathologically, Evans grade ≥III was noted in six patients (17.6%), of which three patients had pathological CR. Thirty patients (88.2%) could receive postoperative adjuvant chemotherapy, and the median time from CS to induction of adjuvant chemotherapy was 1.8 (range 0.7-6.5) months. S-1 was given in 18 patients, GEM in nine patients, GS in one patient, nab-PTX in one patient, and intraperitoneal infusion of PTX combined with intravenous administration of GEM in one patient. Nineteen patients (63.3%) could complete adjuvant chemotherapy.
Postoperative recurrence
Recurrence was confirmed in 18 (52.9%) of 34 patients (Table 3) . Five patients had peritoneal dissemination, four patients had liver metastasis, four patients had lung metastasis, and three patients had remnant pancreatic recurrence. The median duration from CS to recurrence was 12.6 (range 1.6-65) months. Besides, we considered the time to relapse by the recurrence site. The median time to liver metastasis was 4.5 (range 1.6-5.4) months, CAR celiac axis resection, CHAR common hepatic arterial resection, CHASAR common hepatic artery and splenic artery resection, CS conversion surgery, CTx chemotherapy, DP distal pancreatectomy, SSPPD subtotal stomach-preserving pancreaticoduodenectomy, TP total pancreatectomy Two of three patients with recurrence in the remnant pancreas underwent total pancreatectomy as an additional pancreatic resection. After the surgery, systemic chemotherapy with GEM alone or FOLFIRINOX was performed for the patients. Intraarterial infusion chemotherapy with GEM and 5-FU was given in one patient. One patient with peritoneal recurrence underwent intraperitoneal PTX combined with oral administration of S-1. Best supportive care was selected in one patient.
Survival analysis
The DFS curve from the CS is shown in Figure 1 . DFS rates at 1, 3, and 5 years were 82.0%, 41.1%, and 34.3%, respectively. The survival curve of all 34 patients from initial treatment is shown in Figure 2a . The median follow-up period for all patients was 3.25 (range 1.3-12.5)
years. The 1-, 3-, 5-, and 10-year OS rates were 100%, 74.0%, 56.9%, and 33.2%, respectively. The median survival time (MST) was 5.3 years. Furthermore, there were 19 patients who could be observed for 5 years or more from the initial treatment. The survival curve of these 19 patients is shown in Figure 2b . The actual 5-year OS was 47.4% with an MST of 4.0 years. Moreover, the survival curve of 34 patients from CS is shown in Figure 2c . The 1-, 3-, and 5-year OS rates were 80.7%, 51.8%, and 46.6%, respectively, with an MST of 3.8 years. We compared the survival from the initial treatment and from CS between the locally advanced group and the distant metastasis group. Although there was a significant difference between the two groups in the G-W test, no significant difference was observed in the L-R test (G-W test, P = 0.0121; L-R test, P = 0.0971, Fig. 3a ; G-W test, P = 0.0380; L-R test, P = 0.1606, Fig. 3b ). In the comparison of the survival from the initial treatment and from CS in terms of histologic assessment of the degree of NST response, patients with Evans grade ≥III had a better prognosis than those with Evans grade <III, showing a significant difference (G-W test, P = 0.0141; L-R test, P = 0.0092, Fig. 4a ; G-W test, P = 0.0380; L-R test, P = 0.1606, Fig. 4b ). Regarding CA19-9, there is no significant difference in the OS from the initial treatment between the increase, decrease, and no change groups (G-W test, P = 0.4112; L-R test, P = 0.4587). Besides, only three of the nine patients who survived more than 5 years obtained CA19-9 reduction. Moreover, none of the three patients achieved normalization of CA19-9 value.
Discussion
This study revealed the long-term prognosis of patients with UR-PC in whom CS was performed; 1-, 3-, 5-, and 10-year OS rates from initial treatment were 100%, 74%, 56.9%, and 33.2%, respectively, with an MST of 5.3 years (Fig. 2a) . Until now, several studies related to CS for patients with UR-PC have been reported [8] [9] [10] [11] [12] [13] [14] [15] [16] . However, our results revealed the most favorable survival rate among those previous studies. Besides, the actual 5-year OS of 47.4% with an MST of 4.0 years is considered an important data because there have been no reports referring to the survival analysis of patients who could be observed at long term such as 5 years or more as in this study. These values appeared to indicate the possibility of a fair prognostic effect of CS to a certain extent. The therapeutic strategy of CS for patients with UR-PC had a relatively short history and originated from our previous report of 12 patients with UR-PC who responded favorably to NST in 2011 [8] . In this study, CS was expressed as "adjuvant surgical therapy." This cohort Fig. 1 Disease-free survival (DFS) curve from the conversion surgery (CS) of patients who underwent CS. DFS rates at 1, 3, and 5 years were 82.0%, 41.1%, and 34.3%, respectively included four patients with distant metastasis. R0 resection rate was 75%, and 5-year OS from initial treatment was 50%. There were no 5-year survivors in the distant metastasis group, and the locally advanced group had a better prognosis than the distant metastasis group with a significant difference (P = 0.0014). Our present study had the longer follow-up observations, and further cases were added to this previous report. We compared the survival of the distant metastasis group and the locally advanced group in the same manner as reported previously. As a result, no significant difference was observed between the two groups in the L-R test but not in the G-W test (Fig. 3) . The difference between the two analyses might be caused by the small number of patients in the distant metastasis group and be influenced by the early occurrence of hepatic metastasis. As the hepatic metastasis was the second most frequent in the study, the statistical difference analyzed by the L-R test may become significant if we could collect a larger number of patients with UR-M. On the other hand, in this study, we revealed that the survival of patients with Evans grade ≥III was significantly better than that of patients with Evans grade <III (Fig. 4) . Until now, there have been reports on the association between histopathological responses to chemo(radio) therapy and prognosis of patients with PC [21] [22] [23] . Chatterjee et al. [21] reported that 42 (18.8%) of 223 patients with PC who received neoadjuvant chemotherapy showed Evans grade ≥III and that they had better survival rates than patients with Evans grade <III. Moreover, White et al. [22] referred to the possibility that histologic response was useful as a surrogate marker for treatment efficacy. From our results, we consider that it is a very useful information in the management of patients after CS. However, because it is based on the results of resected specimen, it is difficult to select patients with a high probability of good prognosis before surgery. It is needless to say that further analysis should be necessary in the future.
The usefulness of the reduction in CA19-9 level or the maximum standardized uptake value (SUVmax) level of PET has been reported as an indicator for evaluating the treatment effect of preoperative chemo(radio)therapy [13, 24] . In the current study, contrary to previous studies, there was no significant difference in the OS in terms of the change in CA19-9 level, and no patient who survived more than 5 years achieved normalization of CA19-9 level. Based on these results, we estimated that the reduction or normalization of CA19-9 level was not an essential condition for candidates of CS. Conversely, the values of SUVmax differ from one institution to another. Because most patients in our cohort were referred from other hospitals, it was difficult to compare SUVmax value in each patient.
With advances in surgical techniques, extended resection using a combination of vascular surgical procedures for patients with PC could be performed relatively safely, and studies were also conducted on CS with concomitant resection of major arteries such as CA or CHA. Amano et al. [11] reported that CS could be performed in 13 (76.5%) of 17 patients with locally advanced UR-PC, who received chemoradiotherapy as NST. It is noteworthy in this study that all surgical procedures performed in 13 patients were extended resections with concomitant major arterial resection. Therefore, extended resections with concomitant major arterial resection after chemoradiotherapy were acceptable based on these results: R0 resection rate was 92.3%, complication rate was 61.5%, and 1-year OS was 92.8%. However, the median observation period of this study was 436 (range 320-1,170) days, which was shorter than that in other studies. Therefore, prognostic analysis with long-term follow-up is necessary to discuss the prognostic effect of this surgical strategy. We previously based on extended resection when performing CS. However, given the remarkable progress of NST, obtaining tumor shrinkage is possible. Specifically, in cases of CS, diagnosing the extent of tumor invasion accurately due to the influence of NST was difficult, even if multimodal imaging studies were used. Currently, considering this situation, we attempted proactively to minimize surgical invasiveness of CS and avoid concomitant major arterial resection by confirming with intraoperative frozen sections that the periarterial nerve plexus is cancer negative. In this series, it could be performed in four patients, and R0 resection was achieved in all cases. However, whether preserving major artery truly minimizes invasiveness of CS and whether this surgical procedure can affect prognosis are unclear. Hence, it is necessary to accumulate more cases and to have a longer follow-up for patients who undergo "minimally invasive CS."
In this manner, while the therapeutic effect of CS on patients with UR-PC is investigated, progress of chemo (radio)therapy is remarkable, and FOLFIRINOX or GnP regimen is used as first-line chemotherapy for patients with UR-PC [12, 13, [25] [26] [27] . Hackert et al. [13] reported that patients with UR-PC who received FOLFIRINOX as NST had a higher conversion rate and a better prognosis than those who received other regimens, and they advocated that FOLFIRINOX should be the first-line therapy for patients with UR-PC. As the antitumor effect of these regimens is very high, candidates for CS are expected to increase. However, at the same time, prognosis of patients with UR-PC who received NST alone was dramatically improved, and MST exceeded 20 months in recent articles [28, 29] . We should always compare survival analysis by NST alone when examining the prognostic effect of CS. CS is the most invasive surgical therapy. Therefore, at least, the prognostic effect of CS must be always better than that of NST alone. In addition, we clarified that some patients had recurrence earlier after CS, of which liver metastasis occurred the earliest (median time to relapse after CS: 4.5 months). For such patients, CS with high invasiveness could not be considered an effective treatment. Further studies including genome analysis are necessary [30] . If diagnosis of early recurrent patients before CS becomes possible, unnecessary extended surgery can be avoided, and more appropriate treatment for patients with UR-PC can be applied.
This study has some limitations. It was a single-institute and retrospective study with a small number of cases. As all previous studies, including the current study, are retrospective studies, we believe that a prospective study is necessary to define the efficacy of CS. In Japan, PREP-04 trial (UMIN000017793), which is a multi-institutional prospective observational study for investigating the effects of CS on patients with initially UR-PC, is already ongoing. The results of this study must be greatly anticipated. Given that only selected patients responded favorably to NST were targeted among all patients with UR-PC, a selection bias existed. In addition, one of the limitations is that the conversion rate in this series was unclear. Nitsche et al. [12] reported that CS was possible in 4 (28.6%) of 14 patients with UR-PC who received FOLFIRINOX as NST. On the other hand, Hackert et al. [13] reported that CS could be performed in 292 (50.8%) of 575 patients with UR-PC who received NST. Regarding our study cohort, only data of highly selected patients, who were initially diagnosed with UR-PC, judged to have resectable disease following NST in other hospitals, and then referred to our hospital, were collected. Therefore, not only overall conversion rate but also its difference between each unresectable factor could not be considered. Moreover, it may be necessary to consider that CS has an important significance as one of the options of multidisciplinary treatment.
In conclusion, CS may possibly improve the prognosis of patients with UR-PC. Therefore, CS should be considered for patients with UR-PC who obtained a good response by NST for a certain period. Multidisciplinary treatment including CS for patients with UR-PC in close cooperation with oncologists, radiologists, and hepato-biliary-pancreatic surgeons is necessary.
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